Curis, Inc. (CRIS) Director Marc Rubin Acquires 25,000 Shares of Stock

Curis, Inc. (NASDAQ:CRIS) Director Marc Rubin bought 25,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was bought at an average price of $0.98 per share, with a total value of $24,500.00. Following the completion of the acquisition, the director now owns 51,596 shares of the company’s stock, valued at approximately $50,564.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Curis, Inc. (NASDAQ:CRIS) traded down $0.05 during trading on Friday, reaching $0.88. 2,084,090 shares of the company were exchanged, compared to its average volume of 677,276. Curis, Inc. has a 52-week low of $0.88 and a 52-week high of $3.53. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.

Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $2.44 million during the quarter, compared to analysts’ expectations of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. Curis’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. research analysts predict that Curis, Inc. will post -0.41 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Curis, Inc. (CRIS) Director Marc Rubin Acquires 25,000 Shares of Stock” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/11/19/curis-inc-cris-director-marc-rubin-acquires-25000-shares-of-stock.html.

A number of equities research analysts recently issued reports on CRIS shares. Guggenheim started coverage on shares of Curis in a report on Monday, October 23rd. They issued a “buy” rating and a $7.00 target price for the company. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Monday, October 16th. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $6.50.

Hedge funds have recently made changes to their positions in the business. FNY Partners Fund LP lifted its position in Curis by 350.0% during the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 52,500 shares in the last quarter. Bank of America Corp DE lifted its position in Curis by 58.7% during the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 13,448 shares in the last quarter. Prudential Financial Inc. acquired a new position in Curis during the first quarter valued at approximately $105,000. OxFORD Asset Management LLP acquired a new position in Curis during the second quarter valued at approximately $115,000. Finally, Voya Investment Management LLC lifted its position in Curis by 21.8% during the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 12,207 shares in the last quarter. 46.01% of the stock is currently owned by hedge funds and other institutional investors.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply